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Abstract
Background: Most deaths from ovarian cancer are due to metastases that are resistant to
conventional therapies. But the factors that regulate the metastatic process and chemoresistance
of ovarian cancer are poorly understood. In the current study, we investigated the aberrant
expression of human sperm protein 17 (HSp17) in human epithelial ovarian cancer cells and tried
to analyze its influences on the cell behaviors like migration and chemoresistance.
Methods:  Immunohistochemistry and immunocytochemistry were used to identify HSp17 in
paraffin embedded ovarian malignant tumor specimens and peritoneal metastatic malignant cells.
Then we examined the effect of HSp17 overexpression on the proliferation, migration, and
chemoresistance of ovarian cancer cells to carboplatin and cisplatin in a human ovarian carcinoma
cell line, HO8910.
Results: We found that HSp17 was aberrantly expressed in 43% (30/70) of the patients with
primary epithelial ovarian carcinomas, and in all of the metastatic cancer cells of ascites from 8
patients. The Sp17 expression was also detected in the metastatic lesions the same as in ovarian
lesions. None of the 7 non-epithelial tumors primarily developed in the ovaries was
immunopositive for HSp17. Overexpression of HSp17 increased the migration but decreased the
chemosensitivity of ovarian carcinoma cells to carboplatin and cisplatin.
Conclusion:  HSp17 is aberrantly expressed in a significant proportion of epithelial ovarian
carcinomas. Our results strongly suggest that HSp17 plays a role in metastatic disease and
resistance of epithelial ovarian carcinoma to chemotherapy.
Background
Ovarian cancer is the fifth or sixth most common cause of
gynecologic cancer morbidity and mortality in developed
countries [1]. Most deaths from ovarian cancer are caused
by metastases that are resistant to conventional therapies.
Although ovarian cancers metastasize primarily by exfo-
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liation followed by peritoneal implantation, about 40%
of patients with advanced ovarian cancer show lymph
node metastasis and/or extra-abdominal metastasis. The
factors that regulate the metastatic process and chemore-
sistance of ovarian cancer remain poorly understood.
Recent studies suggest that the enhanced expression and
activation of matrix metalloproteinases MMP-2 and
MMP-9 may play a role in ovarian cancer cell migration
[2]. But other factors may also contribute to this malig-
nant behavior. One candidate is human sperm protein 17
(HSp17), a normal tissue specific protein detected in the
primary tumor cells from 70% of the patients with ovar-
ian carcinoma [3].
HSp17 is a protein originally reported to be expressed
exclusively in the testis and whose primary function is
binding to the zona pellucida [4]. In addition to testis and
ejaculated sperm, HSp17 was also detected in ciliated epi-
thelia of the respiratory airways and both the male and
female reproductive systems [5]. Recent evidence sug-
gested that HSp17 was aberrantly expressed in many
malignant tumors, such as multiple myelomas [6], ovar-
ian cancers [7], esophageal squamous cell carcinomas [8],
esthesioneuroblastomas [9], and various histological sub-
types of human nervous system (NS) malignancies,
including neuroectodermal and meningeal tumors [10].
Wang et al. showed that promoter methylation can serve
as the main regulatory mechanism for the expression of
HSp17 in tumor cell lines [11]. Because the function of
the HSp17 in cancer cells is not known, we presume that
this protein may play a role in the function of these cili-
ated cells and may influence the malignant behaviors of
ovarian cancer cells.
In this study, we investigated the frequency of HSp17
expression at the protein level and its cell pattern distribu-
tion in various histological subtypes of human ovarian
tumors by immunohistochemistry. We then examined the
effect of HSp17 overexpression on the migration of an
ovarian cancer cell line, HO8910, and its chemoresistance




A panel of formalin-fixed paraffin-embedded ovarian
tumor specimens were obtained from the archival
resource of Department of Pathology, Jinling Hospital,
consisting of 70 epithelial ovarian carcinomas (EOC),
(median) age 52 (22~80), and 7 non-epithelial malignant
tumors primarily developed in the ovaries (1 germ cell
tumor, 2 malignant mesodermal mixed tumors, 4 sex
cord-stromal tumors), (median) age 38 (25~55). All
tumors were classified according to WHO criteria. HSp17
expression in metastatic cancer cells was measured in
ascitic fluids obtained from 8 of the EOC patients, and in
metastatic tumor tissues obtained from 10 patients with
metastatic ovarian cancer in endometrium, oviduct,
omentum majus, rectal sinuses, vagina and jejunoileum.
Specimen collection and archiving of patient data was
performed with written informed consent and approved
by the ethical committee of the hospital.
Immunohistochemistry
Tissue sections (3 μm) were placed on glass slides, heated
at 60°C for 20 min, and then deparaffinized with xylene
and ethanol. For antigen retrieval, tumor specimens
mounted on glass slides were immersed in preheated anti-
gen retrieval solution (DAKO high pH solution, DAKO)
for 20 min and allowed to cool for 20 min at room tem-
perature. After the inactivation of endogenous peroxidase,
anti-HSp17 monoclonal antibody (purchased from BD
Bioscience Co, clone 21) was added at a concentration of
2 μg·ml-1 and incubated overnight at 4°C. The primary
antibody was detected with an anti-mouse IgG (DAKO).
Diaminobenzidine (DAB) substrate was added for 7 min
followed by washing with deionized water, and hematox-
ylin was applied for 1 min to counterstain the tissue sec-
tions. The tissue sections were dehydrated via graded
ethanols followed by xylene, and coverslips were attached
with permount. The extent of immunohistochemical reac-
tivity was graded as follows: negative; +, 5-25% of malig-
nant cells stained; + +, >25-50% of malignant cells
stained; + + +, >50-75% of malignant cells stained; and +
+ + +, >75% of malignant cells stained. Two independent
reviewers scored it and results were in consensus. Negative
control slides omitting the primary antibody were
included in all assays.
Immunocytochemistry
To investigate the expression of HSp17 in ascetic meta-
static tumor cells, washed cells were cytocentrifuged for 3
min at 800 rpm on a glass slide using a Cytospin-2 centri-
fuge and then fixed with Biofix (Bio-Optica; Milan, Italy),
then treated with anti-Sp17 antibody with the same pro-
tocol as immunohistochemistry.
Cell line and culture conditions
The HO8910 human ovary carcinoma cell line was a gift
from Dr. Liu Qi (Medical School of Nanjing University,
China). It was cultured in DMEM supplemented with
10% fetal bovine serum (FBS) and penicillin-streptomy-
cin at 37°C in a 5% CO2 incubator. In vitro experiments
were done at 70% to 80% confluence. Results from all
studies were confirmed in at least three independent
experiments.BMC Cancer 2009, 9:323 http://www.biomedcentral.com/1471-2407/9/323
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Establishment of cell model with overexpression of HSp17
For experiments regarding the roles of HSp17 in cancer
migration and chemoresistance, an HSp17 and GFP co-
expression vector was constructed and introduced into the
EOC cell line HO8910 in which HSp17 is not expressed.
HSp17 cDNA was amplified by polymerase chain reaction
(PCR) from a plasmid pGEM-T/hSp17 which was con-
structed in our laboratory using human testicular cDNA
and used for generating recombinant HSp17 protein [12].
Purified HSp17 cDNA and green fluorescent protein-pro-
ducing pEGFP-N1 vector were digested by HindIII/KpnI,
and then ligated together by T4 ligase to generate the
recombinant plasmid pEGFP-N1/hSp17. 5 × 105 HO8910
cells were seeded in each well of a 12-well plate and trans-
fection was conducted when the cells grew to 70% conflu-
ence. In vitro DNA transfection was by lipofectamine-
mediated transfection procedure. The cells were incubated
at 37°C under an atmosphere of 5% CO2 and 6 h later, the
media was replaced with DMEM containing 10% FCS.
Stably transfected clones were selected 36 h later by add-
ing G418 (Roche Molecular Biochemicals) at 500 μg·ml-
1. The stable clones were then evaluated for the expression
of hSp17/EGFP by fluorescent microscopy, and con-
firmed by Western blot and immunohistochemistry anal-
ysis. Transfectants with vector pEGFP-N1/hSp17 and
pEGFP-N1 were termed HO8910/hSp17 and HO8910/
EGFP cells, respectively.
Western blotting
Proteins in HSp17/EGFP expressing cells and EGFP
expressing cell lysates (20 μg protein/lane) were separated
by sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) in 12% gels and then transferred to
a nitrocellulose membrane (Amersham Biosciences, Pis-
cataway, NJ). After the blot was blocked in PBS-T with 5%
skim milk for 1 h at 37°C, membrane-bound proteins
were immunolabeled with anti-HSp17 monoclonal anti-
body overnight at 4°C. The membranes were washed
three times. The horseradish peroxidase-conjugated rabbit
anti-mouse IgG antibody was incubated with the mem-
branes for 1 h at RT and subsequently washed three times.
Membranes were then detected with the enhanced chemi-
luminescence method (Santa Cruz Biotechnology, CA)
and x-ray film. Purified recombinant HSp17 protein gen-
erated in our laboratory [12] was used as a positive con-
trol.
In vitro migration assay
Cell migration was examined using Transwell chamber
assay according to the protocol of the manufacturer (Bec-
ton Dickinson Labware, Bedford, MA). Briefly, 2 × 105
HO8910/hSp17 and HO8910/EGFP cells in DMEM plus
1% FBS were placed on each 8.0-μm pore size membrane
insert in 24-well plates. DMEM plus 10% FBS was placed
in the bottom wells as chemoattractants. After 20 h, cells
that did not migrate were removed from the top side of
the inserts with a cotton swab. Cells that had migrated to
the underside of the inserts were stained with crystal violet
and the cells on each insert were counted at 200× magni-
fication.
MTT cell viability assay
The HO8910/hSp17 and HO8910/EGFP cells were
seeded in 96-well plates (Costar; Corning Inc., Corning,
NY) for 24 h and then exposed to various concentrations
of cisplatin or carboplatin (QiLu Pharma. Co. China) for
48 h. The cells were incubated with 10 μl of 2 mg·ml-1 3-
(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium
bromide (MTT, purchased from Sigma Co) in phosphate-
buffered saline (PBS) for 4 h, and the formazan crystals
were lysed with 150 μl of DMSO (dimethyl sulfoxide,
from Sigma Co) for 10 min at 37°C. Absorbance at 570
nm was then measured with a microplate reader (Bio-Rad,
680, Hercules, CA). Normal cell culture and no cell wells
were set as control. All concentrations were tested in trip-
licates. Absorbance values were translated to inhibition
rate by the equation 1-(OD of test concentration-OD of
no cell wells)/(OD of control-OD of no cell wells).
Statistical analysis
All statistical analyses were performed with the SPSS 13.0
software. Differences in proportions were evaluated by the
Fisher's exact test as appropriate. One-way ANOVA was
used for mean comparison. Results were considered statis-
tically significant at the P < 0.05 level.
Results
Immunohistostaining of HSp17
A total of 77 archival ovarian malignancy specimens were
investigated by immunohistochemistry. Positive staining
was observed in 43% (30/70) of epithelial ovarian can-
cers. HSp17 protein was expressed in the adenocarcinoma
cells of all subtypes of epithelial ovarian cancer (Table 1).
The expression patterns of HSp17 we observed in EOC
were always heterogeneous (Figure 1). In contrast to pre-
vious reports [7,8], we found HSp17 mainly localized in
the cytoplasm of a variable number of tumor cells, but
positive staining of the cell surface was also detected. No
reactivity was noted in non-epithelial malignant tumors.
All of the metastatic ascitic fluid cancer cells from the 8
EOC patients were positive for HSp17 (Figure 1). The
Sp17 expression was also detected in the metastatic
lesions was the same as in ovarian lesions.
Co-expression of Sp 17 and GFP in HO8910 cells
The co-expression of Sp17 and GFP in HO8910/hSp17
cells was observed under a fluorescence microscope (Fig-
ure 2A) and confirmed by immunocytochemistry with
anti-HSp17 antibody (Figure 2B). In dividing cells, HSp17
is mostly localized to the cytoplasm and then shifts to theBMC Cancer 2009, 9:323 http://www.biomedcentral.com/1471-2407/9/323
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cell surface (Figure 2B). Western blotting analysis showed
that the fusion protein of Sp17 and GFP was 52 kD, which
is much larger than recombinant HSp17 (Figure 2C, 52
kD and 24.5 kD, respectively).
Sp17 increased the migratory capacity of cells
Transwell chamber assays were performed to compare the
migratory capability of HO8910/hSp17 and HO8910/
EGFP cells. At 20 h, the HO8910/Sp17 cells showed a
~3.2-fold increase in the number of cells migrating
through the polycarbonate membrane (156.6 ± 14.9/HP
for HO8910/hSp17 cells, 39.3 ± 8.53)/HP for HO8910/
EGFP cells, n = 10, P < 0.05; Figure 3).
Effect of Sp17 on chemoresistance
The effects of cisplatin and carboplatin on the growth of
HO8910/hSp17 cells and HO8910/EGFP cells were eval-
uated by measuring cell viability under different concen-
tration of drugs using the MTT assay. The results indicated
that HSp17 expression did not affect the viability of
HO8910 cells that were not treated with drugs. On the
other hand, the resistance to cisplatin and carboplatin was
increased in HSp17 transfectants. The cells transfected
with pEGFP-N1 were much more sensitive to the drugs
(Figure 4). This effect was more obvious when the drug
concentrations were between 15 μg·ml-1and 20 μg·ml-1
for cisplatin, 100 μg·ml-1 and 300 μg·ml-1 for carbopla-
tin. These results strongly suggest that Sp17 participates in
the chemoresistance of ovarian carcinoma without influ-
encing cell proliferation.
Discussion
Previous studies have demonstrated the aberrant expres-
sion of some normal testicular proteins in neoplastic cells.
These proteins collectively form a new class of tumor asso-
ciated antigens called cancer-testis (CT) antigens [13,14].
Furthermore they have become the most extensively stud-
ied antigen group in the field of tumor immunology
[12,15-17]. HSp17 is a highly conserved mammalian pro-
tein that was originally isolated from rabbit epididymal
sperm and testis membranes and has been identified as a
member of CT antigen family. The mRNA encoding
HSp17 has been found to be highly expressed in a number
of in vitro neoplastic cell lines, including lung cancer,
prostate cancer, and osteocarcinoma [18]. HSp17 protein
has been recognized in healthy testis [19], normal ciliated
cells of the male and female reproductive tract [5], human
multiple myeloma cell lines [20], and in malignant lym-
phocytes and various tumoral tissues [6-10]. The immu-
nogenicity and tissue localization of Sp17 made it an
attractive candidate for developing specific active immu-
notherapy procedures. Nakazato et al. identified Sp17 as
a candidate gene related to the chemoresistance of clear
cell carcinoma [21]. Bumm et al. showed that Sp17 can be
used as a marker to discriminate between 2 subsets of pri-
mary esthesioneuroblastomas [9].
Our program's primary focus is to study the clinical rele-
vance of aberrant Sp17 expression in order to identify a
better prognostic marker and new treatment for ovarian
cancer. We analyzed the expression of Sp17 in a panel of
ovarian tumor tissues by immunohistochemistry and
showed that Sp17 was positive in 43% percent of EOC
specimens. We found that Sp17 was present in various
tumor types of EOC. Its expression pattern was heteroge-
neous in all of the positive cancer tissue samples, and
expression did not correlate with the histological subtype
and degree of malignancy. Although late stage (III-IV)
tumors expressed higher amount of Sp17 than early stage
tumors, the statistical analysis did not show a significant
difference (data not shown).
Unexpectedly, we observed that all of metastatic ascitic
fluid cancer cells from eight EOC patients were positive
for Sp17. Therefore, we presume that Sp17 could promote
the migration and metastatic activity of cancer cells. In
order to confirm this hypothesis, we generated a cell
model that over-expressed Sp17 by transfecting Sp17
cDNA into an ovarian cancer cell line, HO8910. HSp17
was present in the cytoplasm and on the cell surface in
these model cells, and induced a significant increase in
HO8910 migration by a transwell assay. Previous reports
[22] and our results show that the HSp17 gene is greatly
induced in metastatic cells. Several recent reports have
implicated Sp17 as having a role in cell-cell adhesion and/
or cell migration in transformed, lymphocytic, and
Table 1: HSp17 expression in EOC by IHC
Negative Positive + + + + + + + + + +
All tumors, n (%) (n = 70) 40 30(43%) 10(14.3%) 6(8.6%) 9(12.9%) 5(7.1%)
Serous 22 15 5 3 3 4
Mucinous 11 6 3 2 1 0
Primary peritoneal carcinoma 3 4 1 1 2 0
Clear cell 2 2 1 0 1 0
Endometroid 2 2 0 0 2 0
Undifferentiated 0 1 0 0 0 1
-, 5%; +, <25%; ++, 25-50%; +++, 50-75%; ++++ >75%.BMC Cancer 2009, 9:323 http://www.biomedcentral.com/1471-2407/9/323
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Immunohistochemistry and immunocytochemistry staining of HSp17 in epithelial ovarian carcinomas Figure 1
Immunohistochemistry and immunocytochemistry staining of HSp17 in epithelial ovarian carcinomas. A. dif-
fuse expression in mucus palillary cystadenocarcinoma; B. diffuse expression in serous palillary adenocarcinoma; C. partis 
expression of HSp17 in serous palillary adenocarcinoma; D. scattered expression in poorly differentiated ovarian serous palil-
lary cystadenocarcinoma; E, F. cells from ascitic fluids. (original magnification, 200×).BMC Cancer 2009, 9:323 http://www.biomedcentral.com/1471-2407/9/323
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Co-expression of Sp17 with EGFP in HO8910/hSp17 cells Figure 2
Co-expression of Sp17 with EGFP in HO8910/hSp17 cells. A. fluorescence microscopy showing expression of GFP. B. 
immunocytochemistry showing expression of Sp17 in HO8910 cells (original magnification, 200×). C. Western blot analysis: 1. 
recombinant HSp17; 2. lysate of HO8910/hSp17 cells; 3. lysate of HO8910/EGFP cells.
HO8910/hSp17 cells have increased migratory capacity Figure 3
HO8910/hSp17 cells have increased migratory capacity. Transwell chamber assay was done to compare the migratory 
capabilities of HO8910/hSp17 (A) and HO8910/EGFP (B) cells. At 20 h, HO8910/hSp17 cells showed a ~3.2-fold increase in 
the number of cells migrating through the membrane (original magnification, 200×).BMC Cancer 2009, 9:323 http://www.biomedcentral.com/1471-2407/9/323
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hematopoietic cells, possibly through its interaction with
extracellular heparan sulphate [23,24] or its binding to
AKAP3.
Although investigators in different laboratories observed
Sp17 in the nucleus, cytoplasm, and on the cell surface,
little knowledge of its function related to its localization
has been reported. The role of Sp17 in promoting heparin
sulphate-mediated adhesion of lymphoid cells has been
proposed by Lacy and Sanderson [23], who showed that
Sp17 expressed on the surface of lymphoid-derived cells
from a patient with plasma cell leukemia promoted cell-
cell adhesion via interaction with the heparin sulphate
chain of syndecan 1.
Among the three functional domains of HSp17 [25,26],
the N-terminal domain is similar to the dimer-interaction
site in the cAMP-dependent protein kinase A (PKA) IIa
regulatory subunit (RII alpha), the central sulphated car-
bohydrate-binding domain is necessary for heparin bind-
ing. Sp17's binding to A-kinase anchoring protein 3
(AKAP3) may reflect a functional need for Ca2+/CaM at
sites along the flagella, where Ca2+/CaM is known to play
a role in motility.
Nakazato et al. showed that Sp17 is differentially
expressed between clear cell carcinoma and serous adeno-
carcinoma of the ovary. They examined the effect of small
interfering RNA targeting the Sp17 gene on the chemore-
sistance of clear cell adenocarcinoma of the ovary to pacl-
itaxel and found that this treatment decreased the
chemoresistance of these cells to paclitaxel [21]. Their
study suggests that expression of the Sp17 gene can be
used as a predictor of the chemoresistance of ovarian can-
HO8910/hSp17 and HO8910/EGFP cells are inhibited by cisplatin and carboplatin differently Figure 4
HO8910/hSp17 and HO8910/EGFP cells are inhibited by cisplatin and carboplatin differently. HO8910/hSp17 had 
higher viability than the control cells under different concentrations of cisplatin (A) and carboplatin (B), and the difference is 
quite significant (*p < 0.05, ** p < 0.05). Bars, SD.BMC Cancer 2009, 9:323 http://www.biomedcentral.com/1471-2407/9/323
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cer to paclitaxel. We also demonstrated that Sp17 plays an
important role in the chemoresistance of the ovarian can-
cer cell line HO8910 to cisplatin and carboplatin, the
other two fist-line chemotherapeutics for ovarian cancer.
Although further investigation is needed to clarify the
functions of Sp17 in ovarian cancer, our study suggests
that expression of the Sp17 gene can be used as a predictor
of the migration and chemoresistance of ovarian cancer to
chemotherapeutics.
In conclusion, we investigated the aberrant expression of
human sperm protein 17 in human epithelial ovarian
cancer cells and its influences on the cell migration and
chemoresistance, and found that HSp17 was aberrantly
expressed in 43% of the patients with primary epithelial
ovarian carcinomas, and in all of the metastatic cancer
cells of ascites from 8 patients; Overexpression of HSp17
increased the migration but decreased the chemosensitiv-
ity of ovarian carcinoma cells to carboplatin and cisplatin.
The results strongly suggest that HSp17 plays a role in
metastatic disease and resistance of epithelial ovarian car-
cinoma to chemotherapy.
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